Good Products, a provider of Enterprise Content Management (ECM) solutions and Clinical Technology Consulting for the pharmaceutical, biotechnology and medical device industries, today announced a major expansion to new UK headquarters in Nottingham, UK.
December 23, 2008-Good Products, a leading provider of Enterprise Content Management (ECM) solutions and Clinical Technology Consulting for the pharmaceutical, biotechnology and medical device industries, today announced a major expansion to new UK headquarters in Nottingham, UK. Good Products has seen a significant expansion of its business delivering electronic document management solutions to the pharmaceutical industry in 2008 and the company anticipates further growth in the healthcare industry during 2009, particularly within the small and mid-sized biopharmaceutical sector. As such the company is moving to new larger premises to continue to support its UK and international customers and to accommodate its expanding team.
Good Products' expansion and continued success reflects the continuing need from the pharmaceutical industry for streamlined and compliant regulatory
document management. The relocation reflects the significant growth experienced by Good Products since its inception in 2006. As a result of its
success the company opened a US office in Irvine, California early in 2008 to support its growing North American client base. The company's new premises in the thriving Lenton Lane business district of Nottingham will accommodate Good Product's team of up to 20 staff including new Business Development Manager Michael Brunner. The team has doubled in the last 12 months and the new offices provide the ideal base for significant expansion during 2009.
Keith Williams, CEO, Good Products, comments: "2008 has been a busy year for Good Products, which was founded as a result of identifying a growing need in the pharmaceutical, biotechnology and life sciences sectors to address regulatory and legal pressures through elements of Enterprise Content Management (ECM). During the last two years we have grown from a small company to a global leader in the area of document management and we look forward to continuing our success from these new premises."
During 2008 Good Products launched its Clinical Technology Consulting division, designed to enable biopharmaceutical sponsors and CROs to optimize their use of clinical technology. Since its inception this division has experienced significant growth inception among the sponsor and CRO communities across North America and Europe.
Good Products has advised on a number of regulatory issues including the now mandatory adoption of the eCTD for regulatory submissions. As regulatory requirements become more stringent and new standards come into practice, effective document management is addressed through the extensive g-docs suite of solutions from Good Products.
For more information on Good Products, please visit www.goodproductsEU.com or email info@goodproductsEU.com.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.